These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29239135)

  • 1. Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway.
    Li W; Yu X; Tan S; Liu W; Zhou L; Liu H
    Cancer Med; 2018 Jan; 7(1):208-218. PubMed ID: 29239135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
    Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
    Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
    [No Abstract]   [Full Text] [Related]  

  • 3. Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization.
    Gao F; Yu X; Li M; Zhou L; Liu W; Li W; Liu H
    Cell Death Dis; 2020 Feb; 11(2):143. PubMed ID: 32081857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3.
    Dai Z; Wang L; Wang X; Zhao B; Zhao W; Bhardwaj SS; Ye J; Yin Z; Zhang J; Zhao S
    Oncol Rep; 2018 Aug; 40(2):867-876. PubMed ID: 29989652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non-small-cell lung carcinoma harbouring EGFR T790M mutations.
    Yang K; Chen Y; Zhou J; Ma L; Shan Y; Cheng X; Wang Y; Zhang Z; Ji X; Chen L; Dai H; Zhu B; Li C; Tao Z; Hu X; Yin W
    Br J Pharmacol; 2019 Dec; 176(24):4609-4624. PubMed ID: 31322286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations.
    Dong Q; Yu P; Ye L; Zhang J; Wang H; Zou F; Tian J; Kurihara H
    Sci Rep; 2019 Apr; 9(1):5692. PubMed ID: 30952931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR.
    Jung SK; Lee MH; Lim DY; Kim JE; Singh P; Lee SY; Jeong CH; Lim TG; Chen H; Chi YI; Kundu JK; Lee NH; Lee CC; Cho YY; Bode AM; Lee KW; Dong Z
    J Biol Chem; 2014 Dec; 289(52):35839-48. PubMed ID: 25368326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and synthesis of novel magnolol derivatives with potent anticancer activity in non-small cell lung cancer.
    Tang H; Zhang Y; Li D; Fu S; Tang M; Wan L; Chen K; Liu Z; Xue L; Peng A; Ye H; Chen L
    Eur J Med Chem; 2018 Aug; 156():190-205. PubMed ID: 30006164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.
    Pal HC; Sharma S; Strickland LR; Agarwal J; Athar M; Elmets CA; Afaq F
    PLoS One; 2013; 8(10):e77270. PubMed ID: 24124611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced apurinic/apyrimidinic endonuclease activity enhances the antitumor activity of oxymatrine in lung cancer cells.
    Wang Z; Xu W; Lin Z; Li C; Wang Y; Yang L; Liu G
    Int J Oncol; 2016 Dec; 49(6):2331-2340. PubMed ID: 27748797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
    Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
    Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldolase A promotes proliferation and G
    Fu H; Gao H; Qi X; Zhao L; Wu D; Bai Y; Li H; Liu X; Hu J; Shao S
    Cancer Commun (Lond); 2018 May; 38(1):18. PubMed ID: 29764507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxymatrine targets EGFR(p-Tyr845) and inhibits EGFR-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells.
    Guo B; Zhang T; Su J; Wang K; Li X
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):353-63. PubMed ID: 25527205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
    BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.
    Wu H; Wang A; Zhang W; Wang B; Chen C; Wang W; Hu C; Ye Z; Zhao Z; Wang L; Li X; Yu K; Liu J; Wu J; Yan XE; Zhao P; Wang J; Wang C; Weisberg EL; Gray NS; Yun CH; Liu J; Chen L; Liu Q
    Oncotarget; 2015 Oct; 6(31):31313-22. PubMed ID: 26375053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.
    Kang HN; Kim SH; Yun MR; Kim HR; Lim SM; Kim MS; Hong KW; Kim SM; Kim H; Pyo KH; Park HJ; Han JY; Youn HA; Chang KH; Cho BC
    Lung Cancer; 2016 May; 95():57-64. PubMed ID: 27040853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
    Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.